Carregant...
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis
With 12 available US Food and Drug Administration approved medications for the treatment of relapsing multiple sclerosis (MS), choosing an initial therapy is no longer a straightforward task. Each disease-modifying therapy (DMT) has a distinct risk–benefit profile and each patient is an individual....
Guardat en:
| Publicat a: | Ther Adv Neurol Disord |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622114/ https://ncbi.nlm.nih.gov/pubmed/26557897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285615598910 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|